洛铂治疗肿瘤的研究进展  

Progression of Iobaplatin for cancer

作　　者：孙娜[1] 杨文燕[1] 

机构地区：[1]山东省医学科学院山东省医药卫生科技信息研究所,济南250062

出　　处：《国际肿瘤学杂志》2012年第12期907-909,共3页Journal of International Oncology

摘　　要：洛铂是第3代铂类抗肿瘤药物。大量临床前药效学研究显示，洛铂能阻断细胞周期的运行，诱导细胞凋亡，从而有效抑制肿瘤细胞增殖，且与顺铂无交叉耐药性。洛铂对多种肿瘤患者亦有较好的疗效，且不良反应轻微，安全性较好。Lobaplatin is the third generation platinum drug. Many studies on pharmacodynamics have confirmed that lobaplatin can block the cell cycle and induce cell apoptosis, and thus inhibits tumor cell prolifeeration effectively. Lobaplatin is not cross-resistant to cisplatin. Besides, it has good curative effect to various kinds of cancer patients with mild adverse reactions, and the patients are well tolerable to it.

关 键 词：肿瘤 药效学 临床研究 洛铂 

分 类 号：R730.5[医药卫生—肿瘤]